-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。12ヶ月目標株価を9ドル引き上げ、293ドルとします。これは、2026年EPS予想(変更なし)の32倍に相当し、過去5年間の平均予想PERとほぼ一致します。2026年EPS予想は8.88ドルから9.16ドルに引き上げ、2027年EPS予想は10.20ドルから10.03ドルに引き下げます。第1四半期決算は予想を上回り、業績見通しも上方修正されましたが、当社は引き続き2つ星(売り)の投資判断を維持します。米国のRevPAR(客室1室あたりの売上高)は、主に高級ホテルとアッパーアップスケールホテルのセグメントから、より重要なミッドスケールホテルの貢献へと拡大しました。経営陣は、これは中低所得層の消費者の回帰によるものとしています。しかしながら、第1四半期決算では、特にこれまで大きな利益貢献を担ってきた高級ホテルにおいて、平均客室単価(ADR)の伸びが鈍化したことも注目すべき点です。 HLTの第2四半期EBITDAガイダンスが10億1,500万~10億3,500万ドルで、市場予想の10億8,100万ドルを下回っていることは、高級ホテルの価格決定力が中級ホテルの販売量増加による相殺よりも速いペースで弱まっていることを示唆しています。需要拡大の傾向は好ましいものの、高級ホテルの追い風の鈍化により、現在の株価水準では上昇余地が限られると考えています。
Related Articles
Telix Says Marketing Authorization Application for Glioma Imaging Candidate Accepted for Review in Europe; Shares Up 3%
Telix Pharmaceuticals (ASX:TLX) said Friday its marketing authorization application filed in Europe for TLX101-Px, its glioma imaging candidate, has been validated and accepted for review, moving into a 210-day active assessment phase.In a statement, the company said it is seeking a broad clinical label, reflective of current clinical practice guidelines, with national marketing authorizations expected to follow shortly after a positive outcome at day 210.The company said it aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications.TLX101-Px is also being developed as a patient selection and response assessment tool for Telix's glioblastoma therapy candidate TLX101-Tx, which has been granted orphan drug designation in Europe and the US, per the statement.The phase 3 IPAX-BrIGHT trial of TLX101-Tx in patients with recurrent glioblastoma has started patient dosing internationally and is launching in multiple European countries, the company said.Telix Pharmaceuticals' shares were up 3% in recent Friday trade.
Zozo's Profit Climbs 6% in Fiscal Year 2025
Zozo's (TYO:3092) profit attributable to owners of the parent rose 5.7% to 47.93 billion yen for the fiscal year 2025 from 45.35 billion yen a year earlier.The shopping mall operator's basic earnings per share increased to 54.11 yen from 50.90 yen a year ago, according to a Tokyo bourse filing on Thursday.Net sales climbed 7.2% to 228.37 billion yen for the full year ended March 31 from 213.13 billion yen in the prior year.The company declared a year-end dividend of 20 yen per share, payable from June 11.For the fiscal year 2026, the company expects attributable profit of 49.7 billion yen, EPS of 56.20 yen, and net sales of 241.9 billion yen.Zozo plans to pay interim and year-end dividends of 20 yen per share each for the year, which is higher than the amount in the year-ago period.
EML Payments Says Regulators Extend Date for Implementation of Required Guarantee Structure
EML Payments (ASX:EML) said the Australian Prudential Regulation Authority (APRA) and Reserve Bank of Australia (RBA) agreed to extend the date for implementation of the required authorized deposit-taking institution guarantee structure, subject to EML Payment Solutions showing "satisfactory progress" towards obtaining the guarantee via periodic reporting, according to a Friday Australian bourse filing.EML Payment Solutions is engaging with several domestic and international financial institutions, as well as legal advisors and trustee service providers, to design the required guarantee structure.The regulators had earlier said that they require the firm to obtain a guarantee from an authorized deposit-taking institution in respect of stored value liabilities for certain EML Payment Solutions programs by Thursday.